Sarepta Therapeutics: Strong Elevidys Sales Drive Upward Revision and Buy Rating

TIPRANKS11-07

Analyst Gil Blum of Needham maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), retaining the price target of $205.00. Gil Bl...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481974130?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-07 19:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481974130","market":"us","top_or_hot":-1,"title":"Sarepta Therapeutics: Strong Elevidys Sales Drive Upward Revision and Buy Rating","media":"TIPRANKS","content":"<div>\n<p>Analyst Gil Blum of Needham maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), retaining the price target of $205.00. Gil Bl...</p>\n\n<a href=\"https://www.tipranks.com/news/blurbs/sarepta-therapeutics-strong-elevidys-sales-drive-upward-revision-and-buy-rating?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n","source":"tipranks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sarepta Therapeutics: Strong Elevidys Sales Drive Upward Revision and Buy Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSarepta Therapeutics: Strong Elevidys Sales Drive Upward Revision and Buy Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-07 19:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/blurbs/sarepta-therapeutics-strong-elevidys-sales-drive-upward-revision-and-buy-rating?utm_source=itigerup.com&utm_medium=referral><strong>TIPRANKS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Analyst Gil Blum of Needham maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), retaining the price target of $205.00. Gil Bl...</p>\n\n<a href=\"https://www.tipranks.com/news/blurbs/sarepta-therapeutics-strong-elevidys-sales-drive-upward-revision-and-buy-rating?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SRPT","symbol_name":"Sarepta Therapeutics","start_time":0,"source_url":"https://www.tipranks.com/news/blurbs/sarepta-therapeutics-strong-elevidys-sales-drive-upward-revision-and-buy-rating?utm_source=itigerup.com&utm_medium=referral","article_id":"2481974130","we_media_id":null,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/sarepta-therapeutics-strong-elevidys-sales-drive-upward-revision-and-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2481974130","pubTimestamp":1730978266,"sourceInfo":{"source_id":"tipranks_highlight","name":"Tipranks"},"weMediaInfo":null,"summary":"Analyst Gil Blum of Needham maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), retaining the price target of $205.00. Gil Bl...","collect":0,"end_time":0,"defaultTopTitle":"tipranks.com","property":["rate","earning"],"viewcount":null,"language":"en","relate_stocks":{"SRPT":"Sarepta Therapeutics"},"translate_title":"Sarepta Therapeutics：Elevidys销售强劲推动上调评级和买入评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRPT":1},"content_text":"Analyst Gil Blum of Needham maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), retaining the price target of $205.00. Gil Bl...","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481974130"}